Results 71 to 80 of about 8,860 (153)

Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection

HIV/AIDS: Research and Palliative Care, 2016
Rustin D Crutchley,1 Rakesh C Guduru,2 Amy M Cheng1 1Department of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston, 2CompanionDX, Houston, TX, USA Abstract: Atazanavir/cobicistat (ATV/c) and darunavir/cobicistat (
Crutchley RD, Guduru RC, Cheng AM,
doaj  

Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model. [PDF]

Braz J Med Biol Res
Chege BM, Mwangi PW, Githinji CG, Bukachi F.   +3 more
europepmc   +1 more source

Minor Contribution of UGT1A1 Inhibition to Atazanavir-Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data. [PDF]

Clin Pharmacol Ther
Dong J, Sharma P, Emara R, Cheung D, Tang W, Zhou D, Boulton DW, Någård M, Park MS.   +8 more
europepmc   +1 more source

Development of a Physiologically Based Model of Bilirubin Metabolism in Health and Disease and Its Comparison With Real-World Data. [PDF]

CPT Pharmacometrics Syst Pharmacol
Sayin AZ, Kuepfer L.
europepmc   +1 more source

Risk Assessment for Drug-Induced Hyperbilirubinemia: A Mechanistic Approach. [PDF]

CPT Pharmacometrics Syst Pharmacol
Kumar R, Kumar A, Alam A, Mundkur Y, Wingrove J.   +4 more
europepmc   +1 more source

Prevalence and correlates of hyperbilirubinemia among people living with HIV (PLHIV) receiving atazanavir boosted with ritonavir (ATV/r). [PDF]

BMC Gastroenterol
Farrokhi H, Shahmohamadi E, Pashaei A, Emadi Koochak H, Nooralioghli Parikhani S, Fathi Amrollah M, Mirzapour P, Dehghan Manshadi SA, SeyedAlinaghi S, Hackett D.   +9 more
europepmc   +1 more source

HIV-1 Resistance to Dolutegravir in Benin: The Need to Improve and Strengthen Therapeutic Patient Education Strategies to Achieve the Third Objective 95 of UNAIDS 95-95-95 Target. [PDF]

Case Rep Infect Dis
Tchiakpe E, Diop-Ndiaye H, Osawe S, Toure-Kane C, Yessoufou A.   +4 more
europepmc   +1 more source

Timeliness of switching to second-line antiretroviral therapy following virologic failure in Dar es Salaam, Tanzania. [PDF]

BMC Res Notes
Thadeo MH, Bwire GM.
europepmc   +1 more source

Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV. [PDF]

Antimicrob Agents Chemother
Tsirizani L, Waalewijn H, Szubert A, Mulenga V, Chabala C, Bwakura-Dangarembizi M, Chitsamatanga M, Rutebarika DA, Musiime V, Kasozi M, Lugemwa A, McIlleron HM, Burger DM, Gibb DM, Colbers A, Denti P, Wasmann RE, CHAPAS-4 trial team.   +17 more
europepmc   +1 more source

Model-based evaluation of the interaction between ritonavir-boosted atazanavir and rifampicin in Ugandan adults with HIV. [PDF]

Br J Clin Pharmacol
Kengo A, Resendiz-Galvan JE, Najjemba L, Mugerwa H, De Nicolò A, D'Avolio A, Atoyebi S, Wiesner L, Svensson EM, Waitt C, Denti P.   +10 more
europepmc   +1 more source